Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michelle Ouyang"'
Autor:
Wei-Ling Tsou, Michelle Ouyang, Ryan R. Hosking, Joanna R. Sutton, Jessica R. Blount, Aaron A. Burr, Sokol V. Todi
Publikováno v:
Neurobiology of Disease, Vol 82, Iss , Pp 12-21 (2015)
Ataxin-3 is a deubiquitinase and polyglutamine (polyQ) disease protein with a protective role in Drosophila melanogaster models of neurodegeneration. In the fruit fly, wild-type ataxin-3 suppresses toxicity from several polyQ disease proteins, includ
Externí odkaz:
https://doaj.org/article/f04b9134a46347b3a6fc91a36e74868b
Autor:
Natalya N Guseva, Aaron D. Bossler, Deqin Ma, Megan I Samuelson, Rofieda R Alwaqfi, Michelle Ouyang
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:998-1004
Recurrent GLI1 gene fusions have been recently described in a subset of soft tissue tumors showing a distinct monotonous epithelioid morphology with a rich capillary network and frequent S100 protein expression. Three different fusion partners—ACTB
Autor:
Michelle Ouyang, Mariko Nakayama, Karra A. Jones, Aristides A. Capizzano, Shotaro Naganawa, John Kim, Toshio Moritani
Publikováno v:
AJR. American journal of roentgenology.
OBJECTIVE. Tumefactive demyelination mimics primary brain neoplasms on imaging, often necessitating brain biopsy. This article reviews the literature for the clinical and radiologic findings of tumefactive demyelination in various disease processes t
Autor:
Maria do Carmo Costa, David Cook, Jason E. Gestwicki, Emily Schapka, Sokol V. Todi, Yemen Yang, Svetlana Fischer, Thomas J. McQuade, Rahil M. Dharia, Duxin Sun, Michelle Ouyang, Gnanada S. Joshi, Mark Dulchavsky, Magdalena I. Ivanova, Henry L. Paulson, Martha J. Larsen, Naila S. Ashraf
Publikováno v:
Brain : a journal of neurology, vol 139, iss 11
No disease-modifying treatment exists for the fatal neurodegenerative polyglutamine disease known both as Machado-Joseph disease and spinocerebellar ataxia type 3. As a potential route to therapy, we identified small molecules that reduce levels of t
Autor:
Svetlana Fischer, Yemen Yang, Beverly L. Davidson, Katiuska Luna-Cancalon, Rahil M. Dharia, Michelle Ouyang, Henry L. Paulson, Maria do Carmo Costa, Edgardo Rodriguez-Lebron, Vikram G. Shakkottai, Lucas Martin-Fishman, Naila S. Ashraf
Publikováno v:
Molecular Therapy. 21(10):1898-1908
Machado–Joseph disease (MJD) is a dominantly inherited ataxia caused by a polyglutamine-coding expansion in the ATXN3 gene. Suppressing expression of the toxic gene product represents a promising approach to therapy for MJD and other polyglutamine
Autor:
Christopher M. Gomez, Wei-Ling Tsou, Sokol V. Todi, Joanna R. Sutton, Ryan R. Hosking, Aaron A. Burr, Xiaofei Du, Michelle Ouyang
Spinocerebellar ataxia type 6 (SCA6) belongs to the family of CAG/polyglutamine (polyQ)-dependent neurodegenerative disorders. SCA6 is caused by abnormal expansion in a CAG trinucleotide repeat within exon 47 of CACNA1A, a bicistronic gene that encod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdcaefd1da5ffa26b93272e93c76e70d
https://europepmc.org/articles/PMC4492400/
https://europepmc.org/articles/PMC4492400/
Autor:
Aaron A. Burr, Jessica R. Blount, Gorica Ristic, K. Matthew Scaglione, Holland Galante, Sokol V. Todi, Wei-Ling Tsou, Michelle Ouyang
Publikováno v:
Nature communications
Polyglutamine repeat expansion in ataxin-3 causes neurodegeneration in the most common dominant ataxia, spinocerebellar ataxia type 3 (SCA3). Since reducing levels of disease proteins improves pathology in animals, we investigated how ataxin-3 is deg
Autor:
K. Matthew Scaglione, Jessica R. Blount, Michelle Ouyang, Aaron A. Burr, Sokol V. Todi, Wei-Ling Tsou
Deubiquitinases (DUBs) are proteases that regulate various cellular processes by controlling protein ubiquitination. Cell-based studies indicate that the regulation of the activity of DUBs is important for homeostasis and is achieved by multiple mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec8a45e86268a867758e411fdc3f0c3
https://europepmc.org/articles/PMC3843061/
https://europepmc.org/articles/PMC3843061/